A 58-year-old male presented with large yellowish choroidal mass lesions with exudative subretinal fluid (SRF) in both eyes. A computed tomography (CT) scan of the thorax revealed a mass lesion in the apical segment of the right upper lobe. Fine needle aspiration cytology (FNAC) of right supraclavicular lymph nodes revealed metastatic mucinous adenocarcinoma. Positron emission tomography-computed tomography scan (PET-CT) showed multiple lymphatic, pulmonary, and skeletal metastases. After six cycles of chemotherapy (platinum doublet and systemic bevacizumab), clinical examination and multimodal imaging showed complete regression of the choroidal lesions. Ours is the first case report of bilateral choroidal metastases from primary pulmonary adenocarcinoma (possibly arising from hazardous occupational exposure in the sericulture industry) that showed complete regression in response to standalone systemic chemotherapy agents, platinum doublet and systemic bevacizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791093 | PMC |
| http://dx.doi.org/10.7759/cureus.76900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.
BMC Cancer
March 2025
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Background: Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients with stable disease (SD) than patients with complete response (CR) or partial response (PR) after atezolizumab plus bevacizumab. Improving OS in patients with SD is an unmet medical need.
View Article and Find Full Text PDFEvaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.
JHEP Rep
March 2025
Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly variable. This study aimed to (i) develop and validate a prognostic prediction model to estimate individual prognosis and (ii) compare it with established models.
View Article and Find Full Text PDFRetinal vasculitis associated with intravitreal bevacizumab injection: A case report.
Arch Soc Esp Oftalmol (Engl Ed)
March 2025
Clínica del Ojo, La Paz, Bolivia.
Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion.
View Article and Find Full Text PDFProposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
J Gastroenterol
March 2025
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Background: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug discontinuation criteria remain unclear. This study aims to investigate drug-off criteria for atezolizumab plus bevacizumab as a proof-of-concept study.
View Article and Find Full Text PDFTreatment outcomes of hepatectomy and systemic chemotherapy based on oncological resectability criteria for hepatocellular carcinoma.
Ann Gastroenterol Surg
March 2025
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery Kobe University Graduate School of Medicine Kobe Hyogo Japan.
Aim: The oncological resectability criteria for hepatocellular carcinoma (HCC) have recently been established (R/BR1/BR2), and validating the outcomes is an urgent issue. This study aimed to analyze the outcomes of hepatectomy and systemic chemotherapy based on the oncological resectability criteria.
Methods: A total of 931 patients in the hepatectomy group and 273 in the systemic chemotherapy group who received atezolizumab/bevacizumab, lenvatinib, or durvalumab plus tremelimumab were recruited.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!